Eli Lilly cuts price of weight-loss drug Zepbound

Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
Key Takeaways Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket.The company also launched new 7.5-mg and 10-mg single-use vials, which cost $499 when refilled every 45 days through Eli Lilly's new "Zepbound Self Pay Journey Program.
Eli Lilly is offering weight loss drug Zepbound at lower prices
Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them coverage for weight loss drugs
Eli Lilly Cuts Zepbound Price Amid Rising Competition
Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition from compounding pharmacies and Novo Nordisk. The FDA has mandated compounders to stop selling copied forms of these drugs following the shortage list updates,
Eli Lilly cuts prices for Zepbound weight-loss drug again
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
Zepbound for Weight Loss: What to Know About This Weight Loss Drug
For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and
Eli Lilly (LLY) Lowers Prices for Weight Loss Drug Zepbound
U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its blockbuster weight loss medication Zepbound in an effort to reach more
These Drugs Could Offset the Side Effects of Weight Loss
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Lilly Offers Weight-Loss Drugs in Vials at a Discount to Fight Competition
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk.
Lilly launches higher dose vials of weight-loss drug for $150 less than injector pen
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur demand for the medicine.
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
ABC News12d
Weight-loss drugs
A study suggests that weight loss medications like Ozempic may help ... Eli Lilly says a new trial showed the key ingredient in its popular drugs Zepbound and Mounjaro helped slash the chance ...
Weight-loss drugs are about to get a lot better
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
The next battle in the weight-loss drug war is focussed on muscle growth
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.